Advance of Seriniquinone Analogues as Melanoma Agents.

Seriniquinone, a marine natural product, displayed potent cytotoxicity and selectivity against melanoma cancer cells. This selectivity, combined with a novel mode of action (MOA), prompted studies to translate a pharmacologically relevant lead. Herein, we report on structure-activity relationships (SARs), and provide a strategy to prepare analogues that retain activity and offer an improved water solubility and isomeric purity. From intermediates made on a gram-scale, derivatives were prepared and evaluated for their antiproliferation activity and melanoma selectivity. Overall these studies provide methods to install side chain motifs that demonstrate a common, and yet unique, biological profile.

A Carbohydrate-Derived Splice Modulator.

Small-molecule splice modulators have recently been recognized for their clinical potential for diverse cancers. This, combined with their use as tools to study the importance of splice-regulated events and their association with disease, continues to fuel the discovery of new splice modulators. One of the key challenges found in the current class of materials arises from their instability, where rapid metabolic degradation can lead to off-target responses. We now describe the preparation of bench-stable splice modulators by adapting carbohydrate motifs as a central scaffold to provide rapid access to potent splice modulators.

Spirohexenolide A targets human macrophage migration inhibitory factor (hMIF).

Spirohexenolides A and B comprise a unique family of spirotetronate natural products. We report on the identification of their binding to and modulation of human macrophage migration inhibitor factor (hMIF). Using an immunoaffinity-fluorescent labeling method, the properties of this interaction are detailed and evidence is provided that hMIF plays a key role in the cytostatic activity of the spirohexenolides.

The antibiotic CJ-15,801 is an antimetabolite that hijacks and then inhibits CoA biosynthesis.

The natural product CJ-15,801 is an inhibitor of Staphylococcus aureus, but not other bacteria. Its close structural resemblance to pantothenic acid, the vitamin precursor of coenzyme A (CoA), and its Michael acceptor moiety suggest that it irreversibly inhibits an enzyme involved in CoA biosynthesis or utilization. However, its mode of action and the basis for its specificity have not been elucidated to date. We demonstrate that CJ-15,801 is transformed by the uniquely selective S. aureus pantothenate kinase, the first CoA biosynthetic enzyme, into a substrate for the next enzyme, phosphopantothenoylcysteine synthetase, which is inhibited through formation of a tight-binding structural mimic of its native reaction intermediate. These findings reveal CJ-15,801 as a vitamin biosynthetic pathway antimetabolite with a mechanism similar to that of the sulfonamide antibiotics and highlight CoA biosynthesis as a viable antimicrobial drug target.

New tetraazaannulene hosts for fullerenes.

Two modifications to the doubly concaved host molecules based on well-known nickel tetraazaannulene complexes have resulted in the preparation of the compounds Ni(NapTMTAA).2benzene, 1,6,8,15,17-tetramethyldinapthalene-5,9,14,18-tetraazacyclotetradecinatonickel(II), and Ni(Cl(4)TMTAA).CH(2)Cl(2), 2,3,11,12-tetrachloro-6,8,15,17-tetramethyldibenzo-5,9,14,18-tetraazacyclotetradecinatonickel(II). When crystallized with C(60) in carbon disulfide, the crystalline, well-ordered, host-guest compounds Ni(NapTMTAA).C(60).2CS(2) and Ni(Cl(4)TMTAA).C(60).2CS(2) were formed. The compounds were characterized by X-ray crystallography. The crystal structures of the precursor host molecules showed very strong host-host interactions, particularly in the case of Ni(Cl(4)TMTAA), which had short Ni...Ni interactions of 3.3860(11) and 3.5888(11) A in the two different dimers in the asymmetric unit; yet, these host-host interactions were entirely destroyed in the resultant host-guest compounds, and C(60) molecules were shown to make use of both cusps of the host macrocycle in the formation of a shape-selective arrangement.

Isolation, structure elucidation, and antitumor activity of spirohexenolides A and B.

In this report, we describe the discovery of a pair of bioactive spirotetronates, spirohexenolides A (1) and B (2), that arose from the application of mutagenesis, clonal selection techniques, and media optimization to strains of Streptomyces platensis. The structures of spirohexenolides A (1) and B (2) were elucidated through X-ray crystallography and confirmed by 1D and 2D NMR studies. Under all examined culture conditions, spirohexenolide A (1) was the major metabolite with traces of spirohexenolide B (2) arising in cultures containing increased loads of adsorbent resins. Spirohexenolide A (1) inhibited tumor cell growth with GI(50) values spanning from 0.1 to 17 microM across the NCI 60 cell line panel. An increased activity was observed in leukemia (GI(50) value of 254 nM in RPMI-8226 cells), lung cancer (GI(50) value of 191 nM in HOP-92 cells), and colon cancer (GI(50) value of 565 nM in SW-620 cells) tumor cells. Metabolite 1 was fluorescent and could be examined on a confocal fluorescent microscope with conventional laser excitation and filter sets. Time lapse imaging studies indicated that spirohexenolide A (1) was readily taken up by tumor cells, appearing through the cell immediately after dosing and subcellularly localizing in the lysosomes. This activity, combined with a unique selectivity in NCI 60 cancer cell line screening, indicates that 1 warrants further chemotherapeutic evaluation.

Bis[1-(1-adamantyliminomethyl)-2-naphtholato-κN,O]cobalt(II).

The title compound, [Co(C(21)H(22)NO)(2)], crystallizes with two mol-ecules in the asymmetric unit. The coordination environments of the two Co(II) ions are distorted tetra-hedral. The primary structural difference between the two independent complex mol-ecules lies in the orientations of their adamantyl groups.